TrialEuropean journal of endocrinology2018

Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.

Gudmundur Johannsson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.